Product logins

Find logins to all Clarivate products below.


EU5 Physician and Payer Perspectives on Improved Renal Therapies Versus Tightening Healthcare Budgets | Physician & Payer Forum | EU5 | 2015

A Survey of Nephrologists and Interviews with Payers in the EU5

Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs)/oral/IV iron and phosphate binders, respectively. The market for renal therapies is poised to expand owing to the growing size of the CKD patient population, as well as the expected launches of novel therapies such as oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors to treat renal anemia (i.e., roxadustat, AKB-6548, GSK-1278863A), an IV iron that could reduce the need for ESAs (i.e., Triferic), an IV calcimimetic (i.e., AMG-416), and iron-based phosphate binders to treat hyperphosphatemia and potentially iron deficiency anemia as well (i.e., Auryxia).

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…